Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose-response relationships with respect to side effects, safety, and efficacy for the treatment of obesity are not known. METHODS: We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition. Participants were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive subcutaneous retatrutide (1 mg, 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg], 8 mg [initial dose, 2 mg], 8 mg [initial dose, 4 mg], or 12 mg [initial dose, 2 mg]) or placebo once weekly for 48 weeks. The primary end point was the percentage change in body weight from baseline to 24 weeks. Secondary end points included the percentage change in body weight from baseline to 48 weeks and a weight reduction of 5% or more, 10% or more, or 15% or more. Safety was also assessed. RESULTS: We enrolled 338 adults, 51.8% of whom were men. The least-squares mean percentage change in body weight at 24 weeks in the retatrutide groups was -7.2% in the 1-mg group, -12.9% in the combined 4-mg group, -17.3% in the combined 8-mg group, and -17.5% in the 12-mg group, as compared with -1.6% in the placebo group. At 48 weeks, the least-squares mean percentage change in the retatrutide groups was -8.7% in the 1-mg group, -17.1% in the combined 4-mg group, -22.8% in the combined 8-mg group, and -24.2% in the 12-mg group, as compared with -2.1% in the placebo group. At 48 weeks, a weight reduction of 5% or more, 10% or more, and 15% or more had occurred in 92%, 75%, and 60%, respectively, of the participants who received 4 mg of retatrutide; 100%, 91%, and 75% of those who received 8 mg; 100%, 93%, and 83% of those who received 12 mg; and 27%, 9%, and 2% of those who received placebo. The most common adverse events in the retatrutide groups were gastrointestinal; these events were dose-related, were mostly mild to moderate in severity, and were partially mitigated with a lower starting dose (2 mg vs. 4 mg). Dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter. CONCLUSIONS: In adults with obesity, retatrutide treatment for 48 weeks resulted in substantial reductions in body weight. (Funded by Eli Lilly; ClinicalTrials.gov number, NCT04881760.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Retatrutide is the first triple agonist (acting on GLP-1/GIP/glucagon receptors) with published phase 2 data in people with obesity as well as in people with T2D.”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [45]
Experimental — accuracy not yet measuredIn the citing paper
“e24.2 (95% CI, e26.6 to e21.8) in the 12 mg with an ID of 2 mg group as compared with e2.1 (95% CI, e3.5 to e0.7) in the placebo group.”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Jastreboff et al, 2023
In the citing paper
“Retatrutide 1-12 mg/week over 48 weeks (primary endpoint for bodyweight: 24 weeks) Up to 22•1% (19•3-24•9) with 12 mg/week Up to 0•5% (0•3-0•6) with 8 mg (initial dose 2 mg)/week High drug discontinuation due to adverse events (up to 16% with 12 mg/week); discontinuation for any reason up to 23•5% (with 4 mg/week); weight plateau not reached Jastreboff et al (2023) 138”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [138]
In the citing paper
“In the retatrutide phase 2 trial for people with overweight or obesity (BMI ≥30 kg/m²), or with a BMI of at least 27 kg/m² with one or more weight-related condition, the mean bodyweight reduction at week 48 in the retatrutide (12 mg once-weekly) groups was up to 24•2% (95% CI 21•8-28•6) compared with 2•1% (0•7-3•5) with placebo.138”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [138]
In the citing paper
“However, these resulted in not-so-rare incidents of therapy discontinuation, and their intensity was clearly linked with higher dosages.”
From Retatrutide—A Game Changer in Obesity Pharmacotherapy (2025) · cites this paper as [39]
114 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Physical Activity Guidelines for Americans
Piercy, K. L., Troiano, R. P., Ballard, R. M., Carlson, S. A., Fulton, J. E., Galuska, D. A., George, S. M., & Olson, R. D. (2018) · JAMA · doi:10.1001/jama.2018.14854 · Cited by 9,755
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114
Self-citationA rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Aminian, A., Al-Kurd, A., Wilson, R., Bena, J., Fayazzadeh, H., Singh, T., Albaugh, V. L., Shariff, F. U., Rodriguez, N. A., Jin, J., et al. (2021) · JAMA · doi:10.1001/jama.2021.19569 · Cited by 375
Cited by
Items 401–500 of 1,139
From pathophysiology to novel approaches for obesity-associated hypertension
Kanbay, M., Yayci, E., Genc, C., Çöpür, S., Aktaş, Ö. Y., Sarafidis, P. A., Covic, A. C., Ortíz, A., & Laffin, L. J. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf218 · Cited by 11
“Overall, 41% of participants on retatrutide 8 mg/week and 30% on 12 mg/week were successfully weaned from at least one antihypertensive medication [85 ].”
Suffredini, G., Gao, W. D., & Dodd‐o, J. M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13133633 · Cited by 19
Glucagon-Like Peptide 1 (GLP-1) Action on Hypothalamic Feeding Circuits
Hwang, E., Portillo, B., & Williams, K. W. (2025) · Endocrinology · doi:10.1210/endocr/bqaf125 · Cited by 10
Current Drug Development Pipeline for MASLD and MASH: Focusing on Cardiovascular Comorbidities
Александровна, П. В., & Okovityi, S. V. (2026) · Biomedicines · doi:10.3390/biomedicines14040909 · Cited by 10
Novel neural pathways targeted by GLP-1R agonists and bariatric surgery
Hankir, M. K., & Lutz, T. A. (2024) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-024-03047-3 · Cited by 16
Knihs, V. M., & Filippin-Monteiro, F. B. (2024) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2024.102956 · Cited by 9
Curbing the Obesity Epidemic: Should GLP-1 Receptor Agonists Be the Standard of Care for Obesity?
Kaplan, J. M., Zaman, A., & Abushamat, L. A. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02097-4 · Cited by 12
“In a phase 2 trial, retratrutide, a GLP-1/GIP/glucagon receptor triple agonist led to 24.2% weight loss in 48 weeks at the highest dose in people with obesity and without diabetes with 93% of participants achieving 10% weight loss [89].”
InfluentialRichards, R., Lunt, W., Whitman, M., Spaltro, G., & Hall, R. (2025) · JMIR Formative Research · doi:10.2196/81912 · Cited by 15
“Users achieved substantial and clinically meaningful weight loss over 12 months, with participants in both the tirzepatide and semaglutide cohorts losing more weight over comparable periods than via pharmacological intervention alone [8-11].”
Emerging Pharmacological Approaches for the Treatment of Arterial Hypertension
Schinzari, F., Montenero, R., Cardillo, C., & Tesauro, M. (2025) · Biomedicines · doi:10.3390/biomedicines13040790 · Cited by 9
“…coexisting condition (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease), retatrutide, a synthetic triple GLP-1, GIP, and a glucagone receptor agonist resulted in a significant reduction of systolic BP ( − 12.1 mmHg) and diastolic BP ( − 8.1 mmHg) at 48 weeks [61].”
InfluentialShen, S., Liao, Q., Gu, L., Zhu, Y., Liu, Y., Zhang, X., Zhang, J., Shi, Q., Sun, Y., Wang, J., et al. (2024) · Acta Materia Medica · doi:10.15212/amm-2023-0041 · Cited by 13
“A phase II trial involving the tri-agonist, retatrutide, showed a dose-dependent increase in heart rate that peaked at 24 weeks and declined thereafter; treatment for 48 weeks resulted in a substantial reduction in body weight [67].”
BackgroundPolyagonists in Type 2 Diabetes Management
Dissanayake, H. A., & Somasundaram, N. P. (2024) · Current Diabetes Reports · doi:10.1007/s11892-023-01530-2 · Cited by 8
“For instance, in a phase 2 trial investigating retatrutride for obesity without T2D, weight loss from baseline by 48 weeks in the group treated with retatrutide 12 mg once a week was 24.2% (95% CI, − 26.6 to − 21.8) [57].”
InfluentialMiramontes‐González, J. P., Rodrigo-Alaíz, Á., Gabella-Martín, M., Calle, D. G., Carretero-Gómez, J., & Corral-Gudino, L. (2026) · Diabetes Therapy · doi:10.1007/s13300-025-01829-1 · Cited by 11
Luo, Y., Jiang, H., Shi, B., Cai, H., Wang, H., Li, S., Qiu, W., Li, Y., Zhou, R., Deng, H., et al. (2025) · Contemporary Clinical Trials · doi:10.1016/j.cct.2025.108150 · Cited by 10
Hoffmann, K., Michalak, M., Rizzo, M., Maggio, V., & Paczkowska, A. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2586703 · Cited by 8
“Beyond dual agonists, polyagonist therapies targeting GLP-1 R, GIPR, GCGR, and even FGF21R are under development, with agents such as retatru-tide (a GIP/GLP-1/GCGR triagonist) and emerging tetragonists showing enhanced weight loss and metabolic profiles in early-phase trials [15,53].”
Tewari, J., Qidwai, K. A., Tewari, A., et al. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2450254 · Cited by 9
Remission of type 2 diabetes: position statement of the Italian society of diabetes (SID)
Capoccia, D., Leonetti, F., Natali, A., Tricò, D., Perrini, S., Sbraccia, P., Guglielmi, V., & On behalf of the Italian Society of Diabetes (SID) (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02317-x · Cited by 11
Espinoza, R. T., & Antongiorgi, Z. D. (2024) · Journal of Ect · doi:10.1097/yct.0000000000000992 · Cited by 8
Steenackers, N., Toumassian, J., Deleus, E., Mertens, A. C., Lannoo, M., Pazmiño, S., van Laar, A. D. E., der Schueren, B. V., & Vangoitsenhoven, R. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1569468 · Cited by 21
Molecular Design of Unimolecular Tetra-Receptor Agonists
Dinsmore, T. C., Cortigiano, J. E., Xiang, S., Spenciner, M. V., Dobbins, A. R., Zhao, R. R., Waldman, B. M., Beinborn, M., & Kumar, K. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c04095 · Cited by 13
Glucagon-Like Peptide 1 Receptor Agonists for Obesity: Efficacy, Side Effects, and Risks
Thota-Kammili, S., Tama, E., & Andrade, M. D. H. (2024) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-024-00452-6 · Cited by 10
Nutrient-Stimulating Hormone-Based Therapies for Obesity
Cristancho, C., Kim, D. W., & Apovian, C. M. (2024) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2024.10.006 · Cited by 8
Oxyntomodulin - past, present and future
Holst, J. J., & ROSENKILDE, M. M. (2025) · Peptides · doi:10.1016/j.peptides.2025.171393 · Cited by 12
“It contains structural elements of all three peptides and has a half-life suitable for weekly administration because of lipidation [62].”
Management of patients with type 2 diabetes and MASLD: An overview and joint statement
Chouik, Y., Canivet, C. M., Julla, J., Mouillot, T., Parlati, L., Rouland, A., Smati, S., Tramunt, B., Anty, R., Boursier, J., et al. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101709 · Cited by 12
Temime, V., Ghanem, O. M., Heimbach, J. K., Diwan, T. S., Tranchart, H., Abdallah, H., Blanchard, C. L., Lontrichard, M., Reche, F., Borel, A., et al. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001310 · Cited by 9
“Finally, in the recent years the development of pharma-cotherapeutic agents for the treatment of obesity has made signi fi cant advances with the introduction of semaglutide and tirzepatide (currently in phase 3 trials) and retatrutide (currently in phase 2 trial) [37] .”
BackgroundThe unexpected role of GIP in transforming obesity treatment
Zandvakili, I., & Pérez–Tilve, D. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.07.022 · Cited by 9
Vekić, J., Zeljković, A., Maggio, V., Rizzo, M., & Medenica, S. (2026) · Diabetes Therapy · doi:10.1007/s13300-025-01828-2 · Cited by 10
“For instance, in the clinical trial for obesity treatment, retatrutide also led to greater reductions in both systolic and diastolic blood pressure than placebo [57].”
InfluentialSaeed, A., Mulukutla, S. R., Thoma, F. W., Lemon, L. S., Koczo, A., Reís, S. E., Marroquin, O. C., & Kip, K. E. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-00775 · Cited by 10
LEAP2 as a therapeutic target in obesity and cardiometabolic disorders
Holm, S. K., Johansen, V. B. I., & Clemmensen, C. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-10007-4 · Cited by 11
“Therefore, the be more effective as an adjunct therapy rather than a stand - alone treatment, given the superior efficacy of currently investigated pharmacotherapies for body weight management observed in clinical trials [36–38, 145, 148–150, 152].”
Madhu, S. V., Kapoor, N., Das, S., Raizada, N., & Kalra, S. (2025) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_680_25 · Cited by 18
Sex differences in GLP-1 signaling across speciesPreprint
Roseberry, T., Grossrubatscher, I., Krausz, T., Wang, Y.-J., Schwartz, M. W., & Tingley, D. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.17.643822 · Cited by 8
“Several studies have highlighted that some of the effects of GLP1R agonists are sex-dependent 20–29 .”
Chee, Y. J., & Dalan, R. (2024) · Biomedicines · doi:10.3390/biomedicines12071386 · Cited by 10
Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies
Alhazmi, A., & le Roux, C. W. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1788698 · Cited by 10
“Consequently, dual GLP-1/glucagon agonists survodutide, and triple GLP-1/GIP/glucagon agonists retatrutide are not spared gastrointestinal adverse events, as glucagon related pro-emetic signaling may offset any potential tolerability bene fi ts from GIP agonism (12, 13, 21).”
InfluentialRen, T., Eslam, M., & Fan, J. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0558 · Cited by 11
“Similarly, the recently developed GIP, GLP-1, and glucagon receptor triple agonist, retatrutide, has been studied in patients with diabetes or obesity 13,14 , and maybe in MASH as well in the near future.”
MethodEngineering Supramolecular Nanofiber Depots from a Glucagon-Like Peptide-1 Therapeutic
Chen, W., Xian, S., Webber, B., DeWolf, E. L., Schmidt, C. R., Kilmer, R., Liu, D., Power, E. M., & Webber, M. J. (2024) · ACS Nano · doi:10.1021/acsnano.4c10248 · Cited by 8
Inotropic effects of retatrutide in isolated human atrial preparations
Neumann, J., Ahlrep, U., Hofmann, B., & Gergs, U. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04421-3 · Cited by 7
Epidemiology of cardiovascular–kidney–metabolic syndrome
Mavromatis, L. A., & Grams, M. E. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01078-w · Cited by 14
Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare
Bhat, S., Fernandez, C. J., Lakshmi, V., & Pappachan, J. M. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i8.107991 · Cited by 9
Advancements in the management of obesity: a review of current evidence and emerging therapies
Abdalla, M. A., Ssemmondo, E., Mark‐Wagstaff, C., & Sathyapalan, T. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2347258 · Cited by 10
“A gastrointestinal adverse event was higher with retatrutide; however, it has a great potential for weight loss [74] Table 1.”
BackgroundMeyer, M., Núñez, J. E., Goyal, P., Silverman, D. N., van Berlo, J. H., & Maharaj, V. (2024) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2024.22 · Cited by 8
“In a phase-2 study of the GLP-1 agonist retatrutide, weight loss was nearly 25% with systolic blood pressure reductions of 12 mmHg in the high-dose group despite a concomitant withdrawal of antihypertensive medications [53] .”
Orioli, L., Thissen, J.-P., & Loumaye, A. (2025) · Clinical Nutrition · doi:10.1016/j.clnu.2025.106547 · Cited by 10
Neff, G. W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70148 · Cited by 13
Ganamurali, N., & Sabarathinam, S. (2026) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.70001 · Cited by 8
Updates on Anti-Obesity Medications in Children and Adolescents
Salama, M., Hassan, D., & Kumar, S. (2025) · Children · doi:10.3390/children12101390 · Cited by 10
“Compared to a − 2.1% reduction in the placebo group, mean weight losses with retatrutide were − 8.7%, − 17.1%, − 22.8%, and − 24.2% at doses of 1 mg, 4 mg, 8 mg, and 12 mg, respectively [98].”
InfluentialRodriguez, N. S., & Hartmann, P. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100058 · Cited by 13
Kim, M.-K., & Kim, H. S. (2024) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2024.228 · Cited by 10
A new era in obesity management
Stanford, F. C. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00887-9 · Cited by 7
Malandris, K., Charalampidis, K., Loomba, R. S., & Sinakos, E. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01621-w · Cited by 12
AI‐Driven De Novo Design of Ultra Long‐Acting GLP‐1 Receptor Agonists
Wei, T., Ma, J., Cui, X., Lin, J., Zheng, Z., Cheng, L., Cui, T., Lin, X., Zhu, J., Ran, X., et al. (2025) · Advanced Science · doi:10.1002/advs.202507044 · Cited by 12
Mahase, E. (2025) · BMJ · doi:10.1136/bmj.r1917 · Cited by 7
Patel, J. P., Hardaswani, D., Patel, J. D., Saiyed, F., Goswami, R. J., Saiyed, T. I., Patel, H., & Amin, T. H. (2025) · Cureus · doi:10.7759/cureus.80321 · Cited by 27
Role of Glucagon-Like Peptide-1 Receptor Agonists in People With Infertility and Pregnancy
Finkle, J., & Brost, B. C. (2025) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000005825 · Cited by 7
Triple G Agonists — A Home Run for Obesity?
Patti, M. (2023) · New England Journal of Medicine · doi:10.1056/nejme2307282 · Cited by 7
Focus on Glucagon-like Peptide-1 Target: Drugs Approved or Designed to Treat Obesity
Zhang, J., Wei, J., Lai, W., Sun, J., Bai, Y., Cao, H., Guo, J., & Su, Z. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041651 · Cited by 9
“Weight loss was enhanced primarily through increased GCGR-mediated energy expenditure and decreased calorie intake driven by GIPR and GLP-1R [95,96].”
Corrao, S., Falcone, F., Mirarchi, L., Amodeo, S., & Calvo, L. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01761-4 · Cited by 13
“Mazdutide (GLP-1/GIP dual agonist) [57], cotadutide (GLP-1/glucagon dual agonist) [58] and retatrutide (GLP-1/GIP/glucagon triple agonist) [59] have shown the capacity to enhance glycaemic control and induce significant weight loss through synergistic mechanisms.”
Variable glucagon metabolic actions in diverse mouse models of obesity and type 2 diabetes
Wu, Y., Chan, A. Y., Hauke, J., Aung, O. H., Foollee, A., Cleofe, M. A. S., Stölting, H., Han, M., Jeppe, K. J., Barlow, C. K., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102064 · Cited by 10
“Additionally, glucagon agonists have been employed in treating patients with type 2 diabetes and obesity, where these treatments have proven effective in reducing body weight and improving glycaemic control [6,7].”
Martins, A. C., de la Torre, B. G., & Alberício, F. (2024) · Exploration of Drug Science · doi:10.37349/eds.2024.00039 · Cited by 11
Old and new anti-obesity drugs
Dodangeh, S., & Hasani‐Ranjbar, S. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01512-5 · Cited by 8
“Gastrointestinal adverse events occurred substantially more often with retatrutide than with placebo; these events were usually mild to moderate in severity and were more common at higher doses of retatrutide [81].”
Causes and consequences of discontinuation of GLP1RAs or tirzepatide
Ceriello, A., Prattichizzo, F., Abdullah, A. R. M. S., Grotta, R. L., Berra, C., McGowan, B. M., Jenkins, A., Cohen, N. D., Nauck, M. A., & Russo, G. T. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-026-01258-5 · Cited by 23
“Based on current clinical evidence, semaglutide and tirzepatide are the most powerful available drugs promoting weight loss 10 , while other drugs in the pipeline with similar mechanisms of action hold even greater potential 11 .”
Shaping the future of cardiometabolic innovation: advances and opportunities
Clemmensen, C., Gerhart‐Hines, Z., Schwartz, T. W., Zierath, J. R., & Sakamoto, K. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01343-5 · Cited by 7
Jordan, G., Young, S., & Alemán, J. O. (2024) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2024.06.006 · Cited by 12
Medical Management of Obesity: Current Trends and Future Perspectives
Calderón, A., Aguilera-Astudillo, M., Rojas, A. P., Dowlatshahi, S., Kansara, A., Shakil, J., & Patham, B. (2025) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1503 · Cited by 8
Kowalska, M. K., El‐Mallul, A., Hudecka, W., Lubojańska, J. E., Lubojański, P. J., Orłowska, S. M., & Bednarczyk, Ł. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27041886 · Cited by 10
Current and Future Pharmacological Interventions for Acquired Hypothalamic Obesity
Roth, C. L., Doelman-Oldenburger, N. J., & van Santen, H. M. (2026) · Drugs · doi:10.1007/s40265-025-02280-z · Cited by 7
(2023) · Nature Medicine · doi:10.1038/s41591-023-02614-y · Cited by 7
Duodenal enteroendocrine cells and GIP as treatment targets for obesity and type 2 diabetes
Bailey, C. J., & Flatt, P. R. (2024) · Peptides · doi:10.1016/j.peptides.2024.171168 · Cited by 6
Himmerich, H. (2025) · Der Nervenarzt · doi:10.1007/s00115-025-01813-x · Cited by 9
Gaffey, R. H., Takyi, A. K., & Shukla, A. P. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2377319 · Cited by 8
“The trial enrolled a total of 338 participants [131].”
Metabolic Syndrome and Pharmacological Interventions in Clinical Development
Javor, E., Šarčević, D., & Rešić, A. (2024) · Diabetology · doi:10.3390/diabetology5030023 · Cited by 9
Salmen, T., Potcovaru, C.-G., Bica, I.-C., Giglio, R. V., Patti, A. M., Stoica, R. A., Ciaccio, M., El‐Tanani, M., Janež, A., Rizzo, M., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17101322 · Cited by 8
“…receptor agonists (GLP-1 Ra) [14–20], to dual incretin tirzepatide in SURMOUNT program [21], to the GLP-1 and glucagon receptor agonist cotatutide [22], or even the triple incretin retatrutide [23], and the first results are promising in how clinicians could take action in the obesity pandemic.”
BackgroundMethodChallenges in the care and treatment of patients with extreme obesity
Stumpf, M. A. M., & Mancini, M. C. (2024) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2023-0335 · Cited by 11
“(7).”
BackgroundInfluentialBrachs, S., Soll, D., Beer, F., Huckauf, N., Konkar, A. A., Spranger, J., Rütten, H., & Mai, K. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae151 · Cited by 7
Patil, S., Jha, N., & Jha, M. K. (2026) · Addictive Behaviors Reports · doi:10.1016/j.abrep.2026.100671 · Cited by 24
Chakravarthy, M. V., Rodríguez, R., Hergarden, A. C., Elliott, M. A., Frías, J. P., ARGÜELLES-TELLO, F. A., Tenorio, E., Rankin, J. E., Wu, J., Krishnan, S., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102291 · Cited by 8
“More recently, treatment with the dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, tirzepa-tide, resulted in substantial weight loss and improved glycemic control among participants with obesity with or without T2D [6,8,10,11].”
Self-citationPark, C., Kim, Y., Raygani, S., & Grunvald, E. L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1630199 · Cited by 7
“A 48-week phase 2 study using a MAD strategy demonstrates a decrease in mean body weight of 8.7% with 1 mg, 17.1% with 4 mg, 22.8% with 8 mg, and 24.2% with 12 mg, compared to 2.1% with placebo (105).”
InfluentialIUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes
Elmendorf, A. J., Yousefian, M., Kim, I., Hardaway, J. A., Habegger, K. M., & Flak, J. N. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108077 · Cited by 8
The impact of GLP-1 agonists on sleep disorders: spotlight on sleep apnea
Mifsud, C. S., Kolla, B. P., Rushlow, D. R., & Mansukhani, M. P. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2574848 · Cited by 8
“A phase II study by Jastreboff et al showed an impressive mean weight reduction of 24.2% after 48 weeks in individuals with obesity and without T2DM who were treated with 12 mg of retatrutide [35].”
InfluentialGLP-1 and GIP may play a role in long-term weight trajectories after gastric bypass
Andrade, S., Lobato, C. B., Machado, M., Hartmann, B., Holst, J. J., de Almeida, R. F., Nora, M. C., Monteiro, M. P., Guimarães, M., & Pereira, S. S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1624001 · Cited by 7
“Retatrutide has shown impressive WL results of up to 24.2% after 48 weeks of treatment (47), which appear to be even more substantial compared to tirzepatide, despite there are no head-to-head clinical trials comparing tirzepatide and retatrutide.”
InfluentialHarrington, J. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10410-0 · Cited by 6
Trending Modalities in Type 2 Diabetes Prevention
Lundgrin, E. L., & Hatipoğlu, B. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf040 · Cited by 8
Lamb, I. M., White, A. D., Willard, F. S., Chalmers, M. J., & Xiao, J. (2025) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5c00079 · Cited by 6
“Furthermore, the triple agonist retatrutide (targeting GLP-1R, GIPR, and GCGR) has shown remarkable effects on weight loss and is currently in advanced clinical trials 12 .”
GOETZ, I. A., Kanu, C., Hoover, A., Jimenez‐Moreno, C., Karn, H., Kimel, M., Neff, L. M., & Boye, K. S. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100220 · Cited by 9
“…to examine the safety and efficacy of four different doses (1, 4, 8 and 12 mg) of once-weekly, subcutaneously administered retatrutide in adults with obesity (BMI ≥ 30 kg/m 2 ) or with overweight (BMI ≥ 27 to 30 kg/m 2 ) and ≥ 1 weight-related complications but without diabetes [12,13].”
InfluentialFiorucci, S., & Urbani, G. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2546812 · Cited by 10
“Considering that both tirzepatide and retatrutide are being developed by the same company, and retatrutide is significantly more potent as anti-obesogenic drug than tirzepatide, it remains uncertain whether both agents will ultimately be pursued as therapeutic options for MASH [58–60].”
Alcaino, C., Reimann, F., & Gribble, F. M. (2024) · The Journal of Physiology · doi:10.1113/jp286293 · Cited by 10
Future potential therapeutics to treat MASH
Mahajan, S., Malladi, N., & Banerjee, S. K. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104451 · Cited by 10
Coleman, S., Lynch, C., Worlikar, H., Kelly, E., Loveys, K., Simpkin, A. J., Walsh, J. C., Broadbent, E., Finucane, F. M., & O'Keeffe, D. T. (2025) · JMIR Diabetes · doi:10.2196/63503 · Cited by 7
“New injectable agents are showing weight loss surpassing 20% and 25% [5].”
Biotechnology Revolution Shaping the Future of Diabetes Management
Kundnani, N. R., Lolescu, B. M., Dinu, A. R., Berceanu-Vaduva, D. M., Dumitrescu, P., Tamaș, T.-P., Sharma, A., & Popa, M.-D. (2024) · Biomolecules · doi:10.3390/biom14121563 · Cited by 7
Obesity and Metabolic Syndrome: Current Insights and Future Directions
Zarkasi, Z., Mudaliar, R. N., Majeed, W., & Syed, A. A. (2025) · British Journal of Hospital Medicine · doi:10.12968/hmed.2025.0127 · Cited by 12
Elangovan, H., Gunton, J. E., Zheng, M., Fan, J.-G., Goh, G. B., Grønbæk, H., & George, J. (2025) · Hepatology International · doi:10.1007/s12072-025-10795-6 · Cited by 7
Physiology and pharmacology of glucagon-like peptide-1 receptor
Куркин, Д. В., Bakulin, D. A., Morkovin, E. I., Petrov, V. I., Strygin, A. V., Koryanova, K. N., Gorbunova, Y. V., Kolosov, Y. A., Ivanova, O. V., Pavlova, E. V., et al. (2024) · Pharmacy & Pharmacology · doi:10.19163/2307-9266-2023-11-4-347-380 · Cited by 13
Camilleri, M. (2024) · The Journal of Physiology · doi:10.1113/jp287535 · Cited by 7
Welling, M. S., van Rossum, E. F. C., & van den Akker, E. L. T. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf004 · Cited by 9
A perspective on intermittent fasting and cardiovascular risk in the era of obesity pharmacotherapy
Eliopoulos, A. G., Gkouskou, K. K., Tsioufis, K. P., & Sanoudou, D. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1524125 · Cited by 8
Gallardo, N., Artigas-Jerónimo, S., Mazuecos, L., & Andrés, A. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1731725 · Cited by 11
“Dual GLP-1/GIP agonists such as tirzepatide, and triple agonists targeting GLP-1, GIP, and glucagon receptors such as retatrutide, integrate complementary pathways to optimize glucose control, enhance fat oxidation and thermogenesis, and improve cardiovascular outcomes (43).”
Obesity Management in South Asian Context
Das, S., Chappalagavi, A. S., Choudhury, A. K., Meher, D., Sahoo, D., Sahu, S. K., & Gupta, S. (2025) · Apollo Medicine · doi:10.1177/09760016251325966 · Cited by 5
“…−15.1% with a 50-mg dose Retatrutide Glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptor agonist Phase II [36] Least squares mean percentage change in body weight was as high as −17.9 at the end of 24 weeks and −24.2 at the end of 48 weeks CagriSema…”
InfluentialAlqatari, S. G., Alwaheed, A., Hasan, M. A., Argan, R. A., Alabdullah, M. M., & Shubbar, M. D. A. (2025) · Medicina · doi:10.3390/medicina61071292 · Cited by 11
“…Reduces HbA1c levels; lowers systolic and diastolic blood pressure; lowers circulating lipid levels [36] ~24% by week 48 [36] Phase 2 trial [36] Subcutaneous,4–12mg,once weekly[36] Triple GLP-1, GIP, and glucagonreceptoragonist[36] Survodutide Improves glucose tolerance and reduces HbA1c…”
InfluentialPharmacotherapy for Obesity: Recent Updates
Fredrick, T. W., Camilleri, M., & Acosta, A. J. (2025) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s497904 · Cited by 33
López, G. P. (2025) · Medicina Clínica · doi:10.1016/j.medcli.2025.107122 · Cited by 5
Ahmed, M., Hassan, M., Tahir, M., Hussain, M., Islam, F., Khan, G. T., Ahsan, M. N., Shafiq, S. S., Ibrahim, A., Uddin, A., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70667 · Cited by 9
Chronic kidney disease, complex conditions, and advancing therapeutics: new hope and challenges
Lees, J. S., Škoberne, A., Zhang, L., Wyatt, C., Fabian, J., Wang, A. Y.-M., Oni, L., & Levin, A. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00653-7 · Cited by 6
McCall, K. D., Walter, D. L., Patton, A., Thuma, J. R., Courreges, M. C., Palczewski, G., Goetz, D. J., Bergmeier, S. C., & Schwartz, F. (2023) · Journal of Inflammation Research · doi:10.2147/jir.s413565 · Cited by 5
“Thus, IOI-214 has the potential to have a profound clinical impact and an exciting novel therapeutic option for the treatment of NAFLD/MAFLD; especially NASH and the more progressive forms of the disease.”
Background
Metadata
- Authors
- Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L.
- Affiliations
- Harvard University (US)
- From the Departments of Medicine (Endocrinology and Metabolism) and Pediatrics (Pediatric Endocrinology), Yale University School of Medicine, New Haven, CT (A.M.J.); the Obesity and Metabolism Institute and Department of Medicine, Harvard Medical School, Boston (L.M.K.); Velocity Clinical Research, Los Angeles (J.P.F.); and Eli Lilly, Indianapolis (Q.W., Y.D., S.G., T.C., A.H., Z.M., M.L.H.).
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-08-10
- Volume
- 389
- Issue
- 6
- Pages
- 514-526
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4382049661
- Cited by
- 1,174
- References
- 28
- Citations by year
- 2026: 399 · 2025: 366 · 2024: 310 · 2023: 96
- FWCI
- 181.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- retatrutide, obesity, weight loss, dose-response relationship, adverse events, GLP-1 receptor agonists, GIP receptor agonist, glucagon receptor agonist, weight-related comorbidities, body mass index
- MeSH terms
- Adult, Double-Blind Method, Female, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Male, Obesity, Weight Loss, Body Mass Index, Treatment Outcome, Receptors, Glucagon, Anti-Obesity Agents, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.